| Role |
Name |
Disclosure |
Details |
| Author | Olga Kozyreva, MD, Fellow, Department of Hematology-Oncology, Tufts University School of Medicine | Nothing to disclose | Details | | Coauthor | Sarah K May, MD, Consulting Staff, Department of Hematology-Oncology, Caritas Carney Hospital, Commonwealth Hematology-Oncology PC | Nothing to disclose | Details | | Coauthor | Karl J D'Silva, MD, Fellow in Hematology/Oncology, Department of Internal Medicine, Breslin Cancer Center, Michigan State University | Nothing to disclose | Details | | Medical Editor | Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Ronald A Sacher, MD, Director of the Hoxworth Blood Center, Professor, Departments of Internal Medicine and Pathology, University of Cincinnati Medical Center | Glaxo Smith Kline Talecris | Details | | CME Editor | Rebecca J Schmidt, DO, FACP, FASN, Clinical Associate Professor of Medicine, West Virginia School of Osteopathic Medicine; Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine | Abbott Genzyme Roche | Details | | Chief Editor | Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Sarah K May, Coauthor |
The contributor discloses no conflict of interest. |
|